Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
Public ClinicalTrials.gov record NCT03748303. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.
Study identification
- NCT ID
- NCT03748303
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 6 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2019
- Primary completion
- Dec 20, 2022
- Completion
- Dec 20, 2022
- Last update posted
- Mar 12, 2026
2019 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II | Los Angeles | California | 90033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Alzheimer Dementia trials
Other public records listing Alzheimer Dementia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07693140: Low-Dose Radiotherapy for Alzheimer's Disease Recruiting
- NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease Active, not recruiting
- NCT04055376: Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease Active, not recruiting
- NCT03926520: Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) Recruiting
- NCT04289402: Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease Active, not recruiting
- NCT05606341: Innate Immunity Stimulation Via TLR9 in Early AD Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03748303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03748303 live on ClinicalTrials.gov.